Samsung Biologics rights offering hits 96.83% as $1.98B M&A nears
What's the deal? Samsung BioLogicsDealroom has a profile for this one. Try Dealroom → has secured most of a US$2.23B rights offering, with its employee and existing-shareholder round reaching a 96.83% subscription rate. Major shareholders Samsung C&TDealroom has a profile for this one. Try Dealroom → and Samsung ElectronicsDealroom has a profile for this one. Try Dealroom → took their full allotments, covering 59.5% of the shares on offer.
Why now? The post-IPO equity raise bankrolls Samsung BioLogics' planned acquisition of Switzerland's PolyPeptide GroupDealroom has a profile for this one. Try Dealroom →, reported as the largest M&A deal in South Korea's pharmaceutical and biotech industry. The firm will apply the entire proceeds to the purchase after trimming the raise by roughly US$281.7M when the issue price was cut.
By the numbers: The new shares priced at US$984.3 each, a 20.4% discount to the prior close. The employee stock ownership association — earlier dogged by concerns over labour strikes — subscribed to 89.30% of its allocation. Korea Investment & SecuritiesDealroom has a profile for this one. Try Dealroom →, Shinhan InvestmentDealroom has a profile for this one. Try Dealroom →, NH Investment & SecuritiesDealroom has a profile for this one. Try Dealroom →, and KB SecuritiesDealroom has a profile for this one. Try Dealroom → underwrote the issuance.
What's the endgame? PolyPeptide makes peptides used in obesity and diabetes treatments, giving Samsung BioLogics production sites in Europe, the US, and India. The deal extends its contract manufacturing business beyond antibodies, mRNA, and antibody-drug conjugates into peptides.
What could go wrong? Completion is not assured. Samsung BioLogics says regulatory approvals remain outstanding and now expects closing toward year-end or in the first quarter of 2027.
The signal: The raise ranks among the largest post-IPO equity rounds in South Korean healthcare over the trailing four years — in the top 1% of 305 comparable deals. With the tender offer drawing about 98% of eligible PolyPeptide shares, Samsung BioLogics is positioning to consolidate its lead as a global contract manufacturer across drug types.
Read more: en.infomaxai.com
Image credit: Generated with Gemini
